Advanced Proteome Therapeutics (STU:0E81) Common Stock: €18.47 Mil (As of Apr. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Advanced Proteome Therapeutics Common Stock?

Advanced Proteome Therapeutics STU:0E81 Common Stock is €18.47 Mil as of Apr. 2023.

Advanced Proteome Therapeutics's quarterly common stock declined from Oct. 2022 (€20.50 Mil) to Jan. 2023 (€18.80 Mil) and declined from Jan. 2023 (€18.80 Mil) to Apr. 2023 (€18.47 Mil).

Advanced Proteome Therapeutics's annual common stock increased from Jul. 2020 (€16.36 Mil) to Jul. 2021 (€16.82 Mil) and increased from Jul. 2021 (€16.82 Mil) to Jul. 2022 (€19.86 Mil).

Advanced Proteome Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Advanced Proteome Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Proteome Therapeutics Common Stock Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.76 16.74 16.36 16.82 19.86

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.58 19.86 20.50 18.80 18.47

Advanced Proteome Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €18.47 Mil mean?
Advanced Proteome Therapeutics (STU:0E81) has a Common Stock of €18.47 Mil as of Apr. 2023. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Advanced Proteome Therapeutics and its competitors.
Is Advanced Proteome Therapeutics' Common Stock too high?
Advanced Proteome Therapeutics' current Common Stock is €18.47 Mil.
How does Advanced Proteome Therapeutics' Common Stock compare to VRTX and REGN?
Advanced Proteome Therapeutics' Common Stock of €18.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Advanced Proteome Therapeutics and its competitors. Advanced Proteome Therapeutics's current Common Stock is €18.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Proteome Therapeutics stock overvalued right now?
Advanced Proteome Therapeutics (STU:0E81) has a current Common Stock of €18.47 Mil. The current Common Stock is €18.47 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Advanced Proteome Therapeutics (STU:0E81), the current Common Stock is €18.47 Mil as of Apr. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced Proteome Therapeutics Business Description

Address 104 8337 Eastlake Drive, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.